Cholinergic connectivity: it's implications for psychiatric disorders
Open accessThe DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Abstract
Acetylcholine has been implicated in both the pathophysiology and treatment of a number of psychiatric disorders, with most of the data related to its role and therapeutic potential focusing on schizophrenia. However, there is little thought given to the consequences of the documented changes in the cholinergic system and how they may affect the functioning of the brain. This review looks at the cholinergic system and its interactions with the intrinsic neurotransmitters glutamate and gamma-amino butyric acid as well as those with the projection neurotransmitters most implicated in the pathophysiologies of psychiatric disorders; dopamine and serotonin. In addition, with the recent focus on the role of factors normally associated with inflammation in the pathophysiologies of psychiatric disorders, links between the cholinergic system and these factors will also be examined. These interfaces are put into context, primarily for schizophrenia, by looking at the changes in each of these systems in the disorder and exploring, theoretically, whether the changes are interconnected with those seen in the cholinergic system. Thus, this review will provide a comprehensive overview of the connectivity between the cholinergic system and some of the major areas of research into the pathophysiologies of psychiatric disorders, resulting in a critical appraisal of the potential outcomes of a dysregulated central cholinergic system.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Glutamate Receptor Ion Channels: Structure, Regulation, and Function
Traynelis, S. F., Wollmuth, L. P., McBain, C. J., Menniti, F. S., Vance, K. M., Ogden, K. K., Hansen, K. B., Yuan, H., Myers, S. J., & Dingledine, R. (2010) · Pharmacological Reviews · doi:10.1124/pr.109.002451 · Cited by 3,568
The Glutamate Receptor Ion Channels
Dingledine, R., Borges, K., Bowie, D., & Traynelis, S. F. (1999) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01394-2 · Cited by 3,554 · cited 1×
“It has long been known that changes in nicotinic receptor sub-unit assembly has functional consequences (Dingledine et al., 1999), therefore the effects of these cytokines would be expected to have an impact on central cholinergic neurotransmission.”
BackgroundSteinbusch, H. W. M. (1981) · Neuroscience · doi:10.1016/0306-4522(81)90146-9 · Cited by 2,415
Dopamine Receptor Binding Predicts Clinical and Pharmacological Potencies of Antischizophrenic Drugs
Creese, I., Burt, D. R., & Snyder, S. H. (1976) · Science · doi:10.1126/science.3854 · Cited by 2,220
Microglia as a source and target of cytokines
Hanisch, U. (2002) · Glia · doi:10.1002/glia.10161 · Cited by 1,645 · cited 1×
“Given that microglia also produce cytokines (Hanisch, 2002), it is not unreasonable to suggest that the cholinergic/inflammation/immune interactions occur within these cells.”
BackgroundAntipsychotic drug doses and neuroleptic/dopamine receptors
SEEMAN, P., LEE, T., CHAU-WONG, M., & WONG, K. (1976) · Nature · doi:10.1038/261717a0 · Cited by 1,622
Neurotransmitters and neuromodulators in the basal ganglia
Graybiel, A. M. (1990) · Trends in Neurosciences · doi:10.1016/0166-2236(90)90104-i · Cited by 1,576
Kynurenines in the mammalian brain: when physiology meets pathology
Schwarcz, R., Bruno, J. P., Muchowski, P. J., & Wu, H.-Q. (2012) · Nature Reviews Neuroscience · doi:10.1038/nrn3257 · Cited by 1,530
CENTRAL CHOLINERGIC SYSTEMS AND COGNITION
Everitt, B. J., & Robbins, T. W. (1997) · Annual Review of Psychology · doi:10.1146/annurev.psych.48.1.649 · Cited by 1,348 · cited 1×
“THE CENTRAL CHOLINERGIC SYSTEM In the human central nervous system, the cholinergic system has evolved into a complex network with three principle components,(i) projections from nuclei of the basal forebrain; these include the medial septal nucleus, the nucleus basalis of Meynert, the vertical nucleus of the diagonal…”
BackgroundLaruelle, M., Abi-Dargham, A., van Dyck, C. H., Gil, R., D'Souza, C. D., Erdos, J., McCance, E., Rosenblatt, W., Fingado, C., Zoghbi, S. S., et al. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.17.9235 · Cited by 1,291
Maeng, S., Zarate, C. A., Du, J., Schloesser, R. J., McCammon, J., Chen, G., & Manji, H. K. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.05.028 · Cited by 1,103
Effects of nicotine on the nucleus accumbens and similarity to those of addictive drugs.
Pontieri, F. E., Tanda, G., Orzi, F., & Chiara, G. D. (1996) · Nature · doi:10.1038/382255a0 · Cited by 1,073 · cited 1×
“Systemic nicotine has been shown to increase dopamine release in the mesolimbic (Imperato et al., 1986; Damsma et al., 1989; Benwell and Balfour, 1994; Nisell et al., 1994a; Pontieri et al., 1996), nigrostriatal (Benwell and Balfour, 1994; Imperato et al.”
BackgroundCholinergic systems in mammalian brain and spinal cord
WOOLF, N. (1991) · Progress in Neurobiology · doi:10.1016/0301-0082(91)90006-m · Cited by 948 · cited 1×
“Cholinergic regulation of dopaminergic function The striatum is densely innervated by tonically active cholinergic interneurons (Butcher and Woolf, 1984; Woolf, 1991; Aosaki et al., 1995; Bennett and Wilson, 1999), which interact closely with dopaminergic neurons to modulate their activity.”
BackgroundThe mesolimbic dopaminergic system is implicated in the reinforcing effects of nicotine
Corrigall, W. A., Franklin, K. B. J., Coen, K. M., & Clarke, P. B. S. (1992) · Psychopharmacology · doi:10.1007/bf02245149 · Cited by 829
Identification of a serotonin/glutamate receptor complex implicated in psychosis
González-Maeso, J., Ang, R. L., Yuen, T., Chan, P., Weisstaub, N. V., López-Giménez, J. F., Zhou, M., Okawa, Y., Callado, L. F., Milligan, G., et al. (2008) · Nature · doi:10.1038/nature06612 · Cited by 803
The human raphe nuclei and the serotonergic system
Hornung, J.-P. (2003) · Journal of Chemical Neuroanatomy · doi:10.1016/j.jchemneu.2003.10.002 · Cited by 742
Prefrontal Dopamine D1Receptors and Working Memory in Schizophrenia
Abi-Dargham, A., Mawlawi, O., Lombardo, I., Gil, R., Martinez, D., Huang, Y., Hwang, D.-R., Keilp, J., Kochan, L., Van Heertum, R., et al. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-09-03708.2002 · Cited by 724
Volk, D. W., Austin, M. C., Pierri, J. N., Sampson, A. R., & Lewis, D. A. (2000) · Archives of General Psychiatry · doi:10.1001/archpsyc.57.3.237 · Cited by 697
Nicotine preferentially stimulates dopamine release in the limbic system of freely moving rats
Imperato, A., Mulas, A., & Di Chiara, G. (1986) · European Journal of Pharmacology · doi:10.1016/0014-2999(86)90629-1 · Cited by 693
Freedman, R., Hall, M., Adler, L. E., & Leonard, S. (1995) · Biological Psychiatry · doi:10.1016/0006-3223(94)00252-x · Cited by 678 · cited 1×
“In tissue from people with schizophrenia, levels of hippocampal α7 receptors have been reported to be decreased (Freedman et al., 1995) and unchanged (Thomsen et al.”
BackgroundEndogenous nicotinic cholinergic activity regulates dopamine release in the striatum
Zhou, F.-M., Liang, Y., & Dani, J. A. (2001) · Nature Neuroscience · doi:10.1038/nn769 · Cited by 585 · cited 3×
“Conversely, there is strong evidence to suggest that nicotine stimulates dopamine release, with receptors containing a β2 subunit playing a significant role (Zhou et al., 2001).”
BackgroundInfluentialTargeting the dopamine D1 receptor in schizophrenia: insights for cognitive dysfunction
Goldman-Rakic, P., Castner, S., Svensson, T., Siever, L., & Williams, G. (2004) · Psychopharmacology · doi:10.1007/s00213-004-1793-y · Cited by 544 · cited 1×
“The development of more specific ligands revealed that stimulating M1/M4 receptors causes potent dopamine release in the striatum and cortex (Bymaster et al., 1994; Ichikawa et al., 2002; Goldman-Rakic et al., 2004).”
BackgroundRegulation of the GABA cell phenotype in hippocampus of schizophrenics and bipolars
Benes, F. M., Lim, B., Matzilevich, D., Walsh, J. P., Subburaju, S., & Minns, M. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0703806104 · Cited by 483
Pharmacology and behavioral pharmacology of the mesocortical dopamine system
Tzschentke, T. M. (2001) · Progress in Neurobiology · doi:10.1016/s0301-0082(00)00033-2 · Cited by 481
Cholinergic Interneurons Control Local Circuit Activity and Cocaine Conditioning
Witten, I. B., Lin, S.-C., Brodsky, M., Prakash, R., Diester, I., Anikeeva, P., Gradinaru, V., Ramakrishnan, C., & Deisseroth, K. (2010) · Science · doi:10.1126/science.1193771 · Cited by 467
Initial phase 2 trial of a nicotinic agonist in schizophrenia
Freedman, R., Olincy, A., Buchanan, R. W., Harris, J. G., Gold, J. M., Johnson, L., Allensworth, D., Guzman-Bonilla, A., Clement, B., Ball, M. P., et al. (2008) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2008.07071135 · Cited by 426 · cited 1×
“, 2009) and is a target for drug development aimed at improving treatments for these disorders (Furey and Drevets, 2006; Freedman et al., 2008; Scarr, 2012).”
BackgroundRole of serotonin in memory impairment.
Buhot, M.-C., Martin, S., & Segu, L. (2000) · Annals of Medicine · doi:10.3109/07853890008998828 · Cited by 419
Furey, M. L., & Drevets, W. C. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.10.1121 · Cited by 417 · cited 2×
“More recently a number of studies have implicated the muscarinic system, in particular the M2 receptor, in the mood disorders (Cannon et al., 2006; Furey and Drevets, 2006; Gibbons et al., 2009).”
BackgroundEpigenetics of the depressed brain: role of histone acetylation and methylation
Sun, H., Kennedy, P. J., & Nestler, E. J. (2013) · Neuropsychopharmacology · doi:10.1038/npp.2012.73 · Cited by 413 · cited 1×
“, 2013) and epigenetic markers (Zhao et al., 2012; Sun et al., 2013) in psychiatric disorders mean that a great deal of progress is being made in understanding the consequences of such factors.”
BackgroundWoo, T.-U. W., Walsh, J. P., & Benes, F. M. (2004) · Archives of General Psychiatry · doi:10.1001/archpsyc.61.7.649 · Cited by 411
Beneyto, M., Kristiansen, L. V., Oni-Orisan, A., McCullumsmith, R. E., & Meador-Woodruff, J. H. (2007) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301312 · Cited by 408
Neurobiology of Dopamine in Schizophrenia
Guillin, O., Abi‐Dargham, A., & Laruelle, M. (2007) · International Review of Neurobiology · doi:10.1016/s0074-7742(06)78001-1 · Cited by 365 · cited 1×
“These findings led to the current view that an imbalance between subcortical and cortical dopaminergic systems is responsible for the symptoms of schizophrenia; a hyperactivity of the dopaminergic system in the subcortical regions (resulting in hyperstimulation of D2 receptors) causes the positive symptoms while hypoa…”
BackgroundRaiteri, M., Leardi, R., & Marchi, M. (1984) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)21528-2 · Cited by 314
Paylor, R., Nguyen, M., Crawley, J. N., Patrick, J., Beaudet, A., & Orr-Urtreger, A. (1998) · Learning & Memory · doi:10.1101/lm.5.4.302 · Cited by 298
Klempan, T. A., Sequeira, A., Canetti, L., Lalovic, A., Ernst, C., ffrench-Mullen, J., & Turecki, G. (2009) · Molecular Psychiatry · doi:10.1038/sj.mp.4002110 · Cited by 294
Marshall, D. L., Redfern, P. H., & Wonnacott, S. (1997) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1997.68041511.x · Cited by 284
Curley, A. A., Arion, D., Volk, D. W., Asafu-Adjei, J. K., Sampson, A. R., Fish, K. N., & Lewis, D. A. (2011) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2011.11010052 · Cited by 283 · cited 1×
“, 2000, 2001), as is cortical GAD67 protein (Curley et al., 2011).”
Drevets, W. C., & Furey, M. L. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.11.021 · Cited by 241
Zhang, W., Yamada, M., Gomeza, J., Basile, A. S., & Wess, J. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-15-06347.2002 · Cited by 224
Nicotinic Modulation of Glutamate and GABA Synaptic Transmission in Hippocampal Neurons
RADCLIFFE, K. A., FISHER, J. L., GRAY, R., & DANI, J. A. (1999) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1999.tb11332.x · Cited by 205
Galantamine for the treatment of cognitive impairments in people with schizophrenia
Buchanan, R. W., Conley, R. R., Dickinson, D., Ball, M. P., Feldman, S., Gold, J. M., & McMahon, R. P. (2008) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2007.07050724 · Cited by 170
Prefrontal cortical modulation of acetylcholine release in posterior parietal cortex
Nelson, C. L., Sarter, M., & Bruno, J. P. (2005) · Neuroscience · doi:10.1016/j.neuroscience.2004.12.007 · Cited by 128
Kawamata, J., & Shimohama, S. (2011) · Journal of Alzheimer's Disease · doi:10.3233/jad-2011-110173 · Cited by 111
Dementia rating and nicotinic receptor expression in the prefrontal cortex in schizophrenia
Martin-Ruiz, C. M., Haroutunian, V. H., Long, P., Young, A. H., Davis, K. L., Perry, E. K., & Court, J. A. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(03)00348-2 · Cited by 100
Kenny, P. J., File, S. E., & Neal, M. J. (2000) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2000.0752409.x · Cited by 100 · cited 3×
“Nicotine was shown to stimulate serotonin release in the hippocampus (Kenny et al., 2000) and frontal cortex (Ribeiro et al.”
BackgroundMiller, A. D., & Blaha, C. D. (2005) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2005.04017.x · Cited by 93
Allen, T. G. J., Abogadie, F. C., & Brown, D. A. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.3979-05.2006 · Cited by 79 · cited 2×
“By contrast, acetylcholine or carbachol administration produce long lasting reductions of stimulus-evoked excitatory postsynaptic potential amplitude in the bed nucleus of the stria terminalis and in basal forebrain neurons (Allen et al., 2006; Guo et al., 2012), an effect supporting the finding that endogenous applic…”
BackgroundThe Reticular Formation and the Limbic System
Strominger, N. L., Demarest, R. J., & Laemle, L. B. (2012) · Noback's Human Nervous System, Seventh Edition · doi:10.1007/978-1-61779-779-8_22 · Cited by 9
Cited by
Brisch, R., Saniotis, A., Wolf, R., Bielau, H., Bernstein, H.-G., Steiner, J., Bogerts, B., Braun, A. K., Jankowski, Z., Kumaritlake, J., et al. (2014) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2014.00047 · Cited by 517
Dopamine, Immunity, and Disease
Channer, B., Matt, S. M., Nickoloff-Bybel, E. A., Pappa, V., Agarwal, Y., Wickman, J., & Gaskill, P. J. (2023) · Pharmacological Reviews · doi:10.1124/pharmrev.122.000618 · Cited by 308
A direct GABAergic output from the basal ganglia to frontal cortex
Saunders, A., Oldenburg, I. A., Berezovskii, V. K., Johnson, C. A., Kingery, N. D., Elliott, H. L., Xie, T., Gerfen, C. R., & Sabatini, B. L. (2015) · Nature · doi:10.1038/nature14179 · Cited by 293
The neurobiological basis of human aggression: A review on genetic and epigenetic mechanisms
Waltes, R., Chiocchetti, A. G., & Freitag, C. M. (2016) · American Journal of Medical Genetics Part B: Neuropsychiatric Genetics · doi:10.1002/ajmg.b.32388 · Cited by 182
New Insights Into Cholinergic Neuron Diversity
Ahmed, N. Y., Knowles, R., & Dehorter, N. (2019) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2019.00204 · Cited by 108
“However, there is still much debate over the mechanisms underlying cholinergic dysfunction in this disease (for review, see Hyde and Crook, 2001; Scarr et al., 2013).”
Background
Metadata
- Authors
- Scarr, E., Gibbons, A. S., Neo, J., Udawela, M., & Dean, B.
- Venue
- Frontiers in Cellular Neuroscience
- Publisher
- Frontiers Media SA
- Published
- 2013
- Volume
- 7
- Pages
- 55-55
- ISSN
- 1662-5102 (ISSN-L)
- OpenAlex
- W2063985393
- Cited by
- 119
- References
- 48
- FWCI
- 5.68
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.